Peptide Profile
Triptorelin
Decapeptyl · Trelstar
Triptorelin is a synthetic decapeptide GnRH agonist with a longer half-life than endogenous GnRH, used clinically to produce controlled hormonal suppression of the reproductive axis via receptor downregulation. Unlike the brief…
- Half-life
- ~7-8 hours (single dose) / ~5-7 weeks (depot form)
- Routes
- subcutaneous, intramuscular
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Triptorelin is
About Triptorelin
Potent GnRH agonist; single pulse stimulates LH/FSH surge and restores HPG axis after suppression (e.g., post-steroid cycle)
Triptorelin is a synthetic decapeptide GnRH agonist with a longer half-life than endogenous GnRH, used clinically to produce controlled hormonal suppression of the reproductive axis via receptor downregulation. Unlike the brief stimulatory effect of native GnRH, continuous or depot administration of triptorelin paradoxically desensitizes pituitary GnRH receptors, producing sustained suppression of LH, FSH, and sex hormone levels through a process known as medical castration. Clinical trials have established triptorelin efficacy for androgen deprivation therapy in prostate cancer, treatment of central precocious puberty, and hormonal management of endometriosis and uterine fibroids. Triptorelin is an FDA-approved prescription medication (Trelstar) available in depot formulations; it requires specialist-supervised monitoring due to an initial hormonal flare on commencement and the significant physiological effects of prolonged sex hormone suppression. Triptorelin for HPTA restart (PCT context) Outside its approved indications, triptorelin has been discussed in post-cycle therapy (PCT) and testosterone replacement therapy (TRT) restart contexts. The rationale is mechanistic: a single low dose of triptorelin triggers a brief, intense LH and FSH pulse before inducing pituitary downregulation — this initial agonist surge may be sufficient to re-sensitise a suppressed hypothalamic-pituitary-gonadal (HPG) axis following prolonged androgen administration that has blunted endogenous LH/FSH production. Some research and anecdotal literature describes single-dose triptorelin protocols as an HPTA restart approach, with the goal of re-initiating endogenous testosterone production. This use is not FDA-approved, not evaluated in randomised controlled trials for this indication, and not a standard of care in any guideline. It represents an off-label research and community-practice area. Triptorelin's mechanism — producing sustained hormonal suppression — means that incorrect dosing or repeated administration would achieve the opposite of the desired restart effect; this context requires qualified clinical supervision. PeptideBase does not endorse off-label use; this is informational context about how the compound is discussed in research and clinical community settings.
Triptorelin Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
What the evidence says about Triptorelin
Research Evidence
based on 6 studies · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
FDA-approved GnRH agonist. Brand: Trelstar (NDA 020726, Jun 2000). Indicated for advanced prostate cancer. Also used off-label for precocious puberty and chemical castration. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
6 sources cited · 1 strong · 4 moderate · 1 weak
1 Meta-analysis · 2 Cohorts · 2 Case seriess · 1 Review
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
J Coll Physicians Surg Pak · 2026
# Summary Research found that in a network meta-analysis of 20 randomized controlled trials involving 2,400 patients with PCOS undergoing IVF/ICSI treatment, triptorelin ranked third among five GnRH agents for improving clinical pregnancy rates (47.9%) and second for improving live birth rates (44.1%), while showing the lowest effectiveness for reducing ovarian hyperstimulation syndrome incidence (15.7%). This study demonstrated that triptorelin occupies a middle-ranking position in efficacy outcomes compared to other GnRH agonists and antagonists studied in PCOS populations.
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.
Int J Womens Health · 2026
# Summary Research found that a prolonged GnRH agonist protocol using triptorelin resulted in successful pregnancy in a 41-year-old woman with advanced maternal age, adenomyosis, endometriosis, and male factor infertility—conditions that typically reduce fertility outcomes. This case study demonstrates that prolonged GnRH agonist protocols may improve in vitro fertilization success in women with multiple adverse prognostic factors, though the authors note that further prospective research is needed to establish broader applicability.
In vitro fertilization-frozen embryo transfer in a patient with gonadotroph adenoma: Exacerbation of ovarian hyperstimulation by triptorelin: a case report.
J Med Case Rep · 2026
Show 3 more sources ↓
Outcomes of GnRH agonist trigger in dydrogesterone-based PPOS versus GnRH antagonist cycles: a retrospective parallel cohort in freeze-all IVF treatment.
Eur J Obstet Gynecol Reprod Biol · 2026
# Summary This study demonstrated that dydrogesterone-based progesterone-primed ovarian stimulation (PPOS) produced comparable laboratory and embryological outcomes to GnRH antagonist cycles when triptorelin was used as a final oocyte maturation trigger in freeze-all IVF treatment. Researchers observed no statistically significant differences between the two protocols across mature oocyte yield, fertilization rates, blastocyst development, and euploidy rates, suggesting PPOS is a viable alternative approach for this clinical scenario.
[Efficacy of the 3-month formulation of triptoreli in children with idiopathic central precocious puberty].
Zhongguo Dang Dai Er Ke Za Zhi · 2026
# Summary Research found that the 3-month formulation of triptorelin effectively suppressed hormone levels and slowed bone maturation in children with idiopathic central precocious puberty over a 12-month treatment period. This study demonstrated that the treatment achieved sustained hormonal suppression with good tolerability and no treatment discontinuations due to adverse effects.
Triptorelin embonate: a 6-month formulation for prostate cancer
Expert Opinion on Pharmacotherapy · 2010
This review describes the pharmacology and clinical evidence for triptorelin embonate 22.5 mg as a 6-month sustained-release LHRH agonist, documenting similar testosterone suppression efficacy and safety profile to the standard 3-month preparation, and reviewing its role in androgen deprivation therapy for prostate cancer and its established applications in endometriosis, uterine fibroids, and central precocious puberty.
Triptorelin Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Reported (unverified — pending clinical review)
No established clinical contraindications
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSTriptorelin
Frequently Asked Questions — Triptorelin
Triptorelin is a synthetic decapeptide GnRH agonist with a longer half-life than endogenous GnRH, used clinically to produce controlled hormonal suppression of the reproductive axis via receptor downregulation. Unlike the brief stimulatory effect of native GnRH, continuous or depot administration of triptorelin paradoxically desensitizes pituitary GnRH receptors, producing sustained suppression of LH, FSH, and sex hormone levels through a process known as medical castration.
HPG axis restart, testosterone restoration, HPTA recovery.
Research on Triptorelin primarily documents effects related to HPG axis restart and testosterone restoration and HPTA recovery. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Triptorelin include ongoing TRT, active hormonal therapy. This is educational information only — consult a qualified healthcare professional before use.
For Triptorelin, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
1 provider in the directory currently offers Triptorelin.
# Summary Research found that in a network meta-analysis of 20 randomized controlled trials involving 2,400 patients with PCOS undergoing IVF/ICSI treatment, triptorelin ranked third among five GnRH agents for improving clinical pregnancy rates (47.9%) and second for improving live birth rates (44.1%), while showing the lowest effectiveness for reducing ovarian hyperstimulation syndrome incidence (15.7%). This study demonstrated that triptorelin occupies a middle-ranking position in efficacy outcomes compared to other GnRH agonists and antagonists studied in PCOS populations.
How to get Triptorelin
Where to buy Triptorelin
1 providerCoverage expanding
No providers currently list Triptorelin. Get notified when one does, or explore providers carrying similar peptides in the Sexual Health category.
Questions to ask your provider
Stay updated on Triptorelin providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.